Clinical Trial Update: A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic study of MK-1602 for acute migraine completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• MK-1602

Snippet

Sponsor: Allergan | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2016-12-09